No Result
View All Result
  • Login
Thursday, August 6, 2026
theadvisertimes.com
  • Home
  • Business
  • Financial Planning
  • Personal Finance
  • Investing
  • Money
  • Economy
  • Markets
  • Stocks
  • Trading
  • Home
  • Business
  • Financial Planning
  • Personal Finance
  • Investing
  • Money
  • Economy
  • Markets
  • Stocks
  • Trading
No Result
View All Result
theadvisertimes.com
No Result
View All Result
Home Startups

Courier Health Raises $50M to Keep More Specialty Therapy Patients on Their Medications – AlleyWatch

by theadvisertimes.com
3 months ago
in Startups
Reading Time: 7 mins read
A A
0
Courier Health Raises M to Keep More Specialty Therapy Patients on Their Medications – AlleyWatch
Share on FacebookShare on TwitterShare on LInkedIn


The life sciences industry continues to generate breakthrough specialty therapies, but the patient support infrastructure connecting those medicines to the people who need them has not kept pace. Siloed data, manual processes, and disconnected systems leave biopharma commercial teams operating without a unified view of the patient journey – a problem so acute that roughly 30% of patients who receive a specialty drug prescription never start that therapy, and 70% discontinue within the first few months. Courier Health addresses this gap directly with the only purpose-built patient experience platform for life sciences commercial teams, connecting disparate data sources, applying AI to proactively surface at-risk patients, and coordinating the full journey from prescription through long-term adherence. Companies using the platform have recorded gains exceeding 15% in patient start rates, a 67% reduction in time-to-start, and seven-fold increases in team productivity – outcomes that translate directly to patients accessing therapies they depend on. The New York City-based company quadrupled the number of therapies managed on its platform in 2025 and more than doubled its headcount to meet accelerating demand.

AlleyWatch sat down with Courier Health Founder and CEO Danny Sigurdson to learn more about the business, its future plans, the company’s recent funding round that brings the total funding raised to $70.5M, and much, much more…

Who were your investors and how much did you raise?

We raised a $50M Series B led by Oak HC/FT, with participation from our existing investors Norwest and Work-Bench. We’re thrilled to partner with Oak HC/FT, a team that has a deep appreciation for what it takes to build lasting infrastructure and impact in healthcare, and we’re grateful to continue our partnership with Irem Rami from Norwest and Jess Lin from Work-Bench.

Tell us about the product or service that Courier Health offers.

Courier Health provides the only purpose-built technology platform for life sciences companies to engage and support patients. We integrate data across systems and leverage AI at every layer of the platform to orchestrate more seamless experiences. This means that biopharma commercial teams can more efficiently and effectively engage stakeholders across the patient journey to drive better health outcomes.

What inspired the start of Courier Health?

The life sciences industry has seen tremendous clinical advancements, but as therapies have gotten more specialized and patient journeys more complex, the technology enabling the critical commercial teams responsible for supporting patients and providers have fallen behind. Siloed data, manual processes, and limited visibility mean that even when a patient reaches diagnosis and prescription, 30% never start that therapy and 70% discontinue within the first few months. At the time of Courier Health’s founding, it was clear that the market – and most importantly, patients and loved ones – were demanding something better. Technology was also advancing to a point where it could deliver. It’s rare to have an opportunity to work at the intersection of solving real business problems, creating tangible value, and meaningfully impacting and helping peoples’ lives. It’s a unique and rewarding opportunity that we don’t take for granted.

How is Courier Health different?

Since day one, we’ve been on a mission to solve one of the most challenging and meaningful opportunities in healthcare, which is reinventing how the hundreds of millions of people living with rare diseases and chronic conditions are supported. We’re 100% focused on improving the biopharma patient experience, and we’ve built our system from the ground up to power more seamless journeys to critical therapies. That applies to everything from how we connect data, to how we design and structure the system to help Field Access and Patient Services teams prioritize their day, to how we leverage AI advancements to automate processes at scale.Our team operates in the same way: we focus on the outcome we’re trying to achieve and apply first principles thinking to come up with creative and impactful solutions.

What market does Courier Health target and how big is it?

Our answer here hasn’t changed much since our Series A! There are hundreds of biopharma manufacturers, thousands of specialty therapies on the market or in development, and hundreds of millions of patients and families who depend on these medicines. We remain laser focused on enabling and empowering commercial teams with the technology they need to be more efficient and effective and to improve the overall patient experience.

What’s your business model?

Our platform is licensed to biopharma companies. We also have an incredible Client Solutions team that partners with our customers from early conversations, implementation and go-live through steady-state and expansion. We’re proud our product is built and supported entirely in-house by our team here in New York.

How has the business changed since we last spoke after Courier Health’s Series A in the summer of 2024?

Our business and team have grown a ton, but our mission, and our commitment to innovating alongside our customers hasn’t changed at all. There’s incredible market momentum, and we’re moving fast to meet it. Last year, we quadrupled the number of platforms on our therapy and more than doubled our team to keep pace. We’ve strengthened our core offerings and continue to scale our AI capabilities to ensure our customers are successful.

We also hosted our 2nd annual Patient Innovators Summit last October here in NYC, including launching the first-ever Patient Innovators Awards, and just published our annual , benchmarking more than 170 biopharma commercial leaders around the state of the industry, AI, and more.

What was the funding process like?

Having strong client partners, program outcomes, and the continued support of Norwest and Work-Bench gave us a strong foundation to work from. We’re grateful that the process moved quickly, and that we found the right partner in Oak HC/FT, a firm with an incredible track record in healthcare that understands the opportunity and impact of what we’re building.

What are the biggest challenges that you faced while raising capital?

Time is always the biggest constraint in a startup environment! Fortunately, we were able to act opportunistically and meet with investors who understand the size and urgency of what we’re tackling.

What factors about your business led your investors to write the check?

I think it ultimately comes down to the scale of the problem, the strength of our platform and team, and most importantly, the outcomes our customers are seeing. Companies who choose Courier Health are achieving double-digit improvements in start rates, 6-month persistency, and overall team productivity. Ultimately, that means patients can access therapies that meaningfully impact their lives, and what’s good for patients is good for business.

I think it ultimately comes down to the scale of the problem, the strength of our platform and team, and most importantly, the outcomes our customers are seeing. Companies who choose Courier Health are achieving double-digit improvements in start rates, 6-month persistency, and overall team productivity. Ultimately, that means patients can access therapies that meaningfully impact their lives, and what’s good for patients is good for business.

What are the milestones you plan to achieve in the next six months?

We remain focused on scaling our platform and AI advantage, attracting top-notch talent, and growing our customer base. On the product side, that means additional AI agents designed and trained specifically for this industry that can work autonomously to handle tasks such as intake processing, benefits checks, and responding to information requests. On the go-to-market side, we’re continuing to bring our technology to more customers searching for an innovative solution to power the patient experience.

I’d be remiss if I didn’t mention that we’re hiring across almost every department! In the next six months, we’ll grow our team, move into new office space, and continue to challenge the status quo of how biopharma commercial teams operate.

What advice can you offer companies in New York that do not have a fresh injection of capital in the bank?

The word I probably use more than anything at Courier Health is “focus.” There is a saying I love, which is “more companies die of indigestion than starvation.” My advice to any startup would be the same thing that I tell my team: Stay maniacally focused on our customers and their outcomes. Get in the trenches with them, understand where their pain points are, and then work tirelessly to deliver the most innovative solution possible. The companies that earn customer trust will find a path forward.

Where do you see the company going now over the near term?

We serve customers to ultimately serve patients. There is no shortage of opportunity for us to continue doing that, so it is our infinite north star. Near term, that means continued investment in our product and agentic capabilities, investing in enabling customers and partners to be successful with the platform, and continuing to hire and retain world-class talent here in New York City.

What’s your favorite spring destination in and around the city?

Washington Market Park in Tribeca. It’s great for kids, and they do a wonderful job with the flowers and local events. A perfect spring weekend for me is spending time outside with my family, and we often do that in that park.

NYC Tech Daily Email

You are seconds away from signing up for the hottest list in NYC Tech!

Sign up today



Source link

Tags: 50MAlleyWatchCourierHealthMedicationspatientsRaisesSpecialtytherapy
ShareTweetShare
Previous Post

Ted Cruz confirms ‘dirty little secret’ about Trump Accounts, and it could change Social Security. Protect yourself now

Next Post

Camtek beats analysts, raises guidance but stock falls sharply

Related Posts

Why Transparency Wins Long-Term in Business: The Competitive Advantage Most Companies Ignore

Why Transparency Wins Long-Term in Business: The Competitive Advantage Most Companies Ignore

by theadvisertimes.com
August 5, 2026
0

When people talk about business growth, the conversation usually centers around the visible levers that naturally attract attention, such as...

The Dunning-Kruger effect isn’t what everyone thinks it is: the original 1999 study found bottom-quartile performers overestimated their standing by about 50 percentile points, not that confident people are stupid

The Dunning-Kruger effect isn’t what everyone thinks it is: the original 1999 study found bottom-quartile performers overestimated their standing by about 50 percentile points, not that confident people are stupid

by theadvisertimes.com
August 5, 2026
0

The Dunning-Kruger effect may be the most misused finding in pop psychology, and the way people misuse it often says...

The AlleyWatch July 2026 New York Venture Capital Funding Report – AlleyWatch

The AlleyWatch July 2026 New York Venture Capital Funding Report – AlleyWatch

by theadvisertimes.com
August 4, 2026
0

New York City startups raised $1.81B across 53 deals in July 2026, a purposeful step down from June’s exceptional $3.90B...

The men who consume the most information — podcasts queued, newsletters unread, tabs left open for weeks — are often the ones who have quietly stopped asking whether any of it is changing how they think

The men who consume the most information — podcasts queued, newsletters unread, tabs left open for weeks — are often the ones who have quietly stopped asking whether any of it is changing how they think

by theadvisertimes.com
August 4, 2026
0

I know a guy with eleven podcast episodes queued, forty-something newsletters sitting unread, and a browser with so many tabs...

The Value Creation Engine: How Growth Equity Firms Turn Strategy Into Results

The Value Creation Engine: How Growth Equity Firms Turn Strategy Into Results

by theadvisertimes.com
August 3, 2026
0

You know the pattern. The value creation plan is sharp, the management team agrees, and the initiatives get owners, milestones,...

The idea that Gen Z is lazy misreads the data: full-time workers aged 20 to 24 averaged 40.5 hours a week, and visible enthusiasm is not the same as effort

The idea that Gen Z is lazy misreads the data: full-time workers aged 20 to 24 averaged 40.5 hours a week, and visible enthusiasm is not the same as effort

by theadvisertimes.com
August 3, 2026
0

The 74% figure is real, but it does not mean what the lazy-Gen-Z argument needs it to mean. ResumeBuilder reported...

Next Post
Camtek beats analysts, raises guidance but stock falls sharply

Camtek beats analysts, raises guidance but stock falls sharply

AI godfather warns hyperintelligent AI with its own ‘preservation goals’ could make humans extinct

AI godfather warns hyperintelligent AI with its own ‘preservation goals’ could make humans extinct

  • Trending
  • Comments
  • Latest
SEC pushes private market access, but retail is already in

SEC pushes private market access, but retail is already in

July 16, 2026
How I Maximize My Sapphire Reserve Dining Credit

How I Maximize My Sapphire Reserve Dining Credit

July 10, 2026
The Weekly Notable Startup Funding Report: 6/22/26 – AlleyWatch

The Weekly Notable Startup Funding Report: 6/22/26 – AlleyWatch

June 21, 2026
The 10 Largest NYC Tech Startup Funding Rounds of June 2026 – AlleyWatch

The 10 Largest NYC Tech Startup Funding Rounds of June 2026 – AlleyWatch

July 6, 2026
The Weekly Notable Startup Funding Report: 7/20/26 – AlleyWatch

The Weekly Notable Startup Funding Report: 7/20/26 – AlleyWatch

July 20, 2026
The Hidden Cost of Chaos: Challenges with Spreadsheet-Based Channel Management in 2026

The Hidden Cost of Chaos: Challenges with Spreadsheet-Based Channel Management in 2026

May 6, 2026
Australian shares suffer worst fall since pandemic

Australian shares suffer worst fall since pandemic

0
Factbox-Tech companies tap debt, equity to fund AI and cloud expansion

Factbox-Tech companies tap debt, equity to fund AI and cloud expansion

0
One in four Canadians own crypto, says OSC survey

One in four Canadians own crypto, says OSC survey

0
Vacation Rentals Are Officially on Sale: Where They’re Worth Buying

Vacation Rentals Are Officially on Sale: Where They’re Worth Buying

0
Trump’s Commerce Department as Venture Capitalist: Political Investment at its Worst

Trump’s Commerce Department as Venture Capitalist: Political Investment at its Worst

0
Britannia Q1 Results: Profit rises 14% to Rs 593 crore on volumes, price rise

Britannia Q1 Results: Profit rises 14% to Rs 593 crore on volumes, price rise

0
Factbox-Tech companies tap debt, equity to fund AI and cloud expansion

Factbox-Tech companies tap debt, equity to fund AI and cloud expansion

August 6, 2026
Britannia Q1 Results: Profit rises 14% to Rs 593 crore on volumes, price rise

Britannia Q1 Results: Profit rises 14% to Rs 593 crore on volumes, price rise

August 6, 2026
OraSure expects Q3 revenue of .5M-.5M while delaying InteliQuick CT/NG FDA clearance beyond 2026 (NASDAQ:OSUR)

OraSure expects Q3 revenue of $29.5M-$32.5M while delaying InteliQuick CT/NG FDA clearance beyond 2026 (NASDAQ:OSUR)

August 6, 2026
GH Research Releases Q2 2026 Financial Results

GH Research Releases Q2 2026 Financial Results

August 6, 2026
Your Processes Are The Weakest Part Of Your AEO Strategy

Your Processes Are The Weakest Part Of Your AEO Strategy

August 6, 2026
Ooredoo teams up with Nvidia and Nokia to launch 1 GW AI platform in Indonesia

Ooredoo teams up with Nvidia and Nokia to launch 1 GW AI platform in Indonesia

August 6, 2026
theadvisertimes.com

Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.

CATEGORIES

  • Business
  • Cryptocurrency
  • Economy
  • Financial Planning
  • Investing
  • Market Analysis
  • Markets
  • Money
  • Personal Finance
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • Factbox-Tech companies tap debt, equity to fund AI and cloud expansion
  • Britannia Q1 Results: Profit rises 14% to Rs 593 crore on volumes, price rise
  • OraSure expects Q3 revenue of $29.5M-$32.5M while delaying InteliQuick CT/NG FDA clearance beyond 2026 (NASDAQ:OSUR)
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • About Us
  • Contact Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Business
  • Financial Planning
  • Personal Finance
  • Investing
  • Money
  • Economy
  • Markets
  • Stocks
  • Trading

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.